Production (Stage)
Jasper Therapeutics, Inc.
JSPR
$6.03
$0.020.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.73% | -46.68% | -6.23% | 9.31% | 3.73% |
| Total Depreciation and Amortization | -3.13% | -13.43% | 96.01% | 8.73% | 5.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.95% | 69.97% | 80.21% | 49.30% | -52.50% |
| Change in Net Operating Assets | -8.46% | 158.40% | -52.89% | -31.37% | -478.54% |
| Cash from Operations | -45.16% | -28.25% | -17.29% | 12.00% | -52.26% |
| Capital Expenditure | -- | 58.26% | -- | -1,327.27% | 3.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 116.00% | 66.96% | -- | -1,327.27% | 3.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 1,132.14% | -75.00% | -49.16% | -53.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 227.31% | -75.00% | 159.34% | -53.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.30% | -22.88% | -19.86% | 14.22% | -65.35% |